Clinical Translational Research
Putative Tumor Suppressor Genes EGR1 and BRSK1 Are Mutated in Gastric and Colorectal CancersChoi E.J.a · Yoo N.J.a · Kim M.S.a · An C.H.b · Lee S.H.a
Departments of aPathology and bGeneral Surgery, College of Medicine, The Catholic University of Korea, Seoul, Korea
Do you have an account?
- Rent for 48h to view
- Buy Cloud Access for unlimited viewing via different devices
- Synchronizing in the ReadCube Cloud
- Printing and saving restrictions apply
Rental: USD 8.50
Cloud: USD 20.00
Article / Publication Details
Objective: The transcription factor-encoding EGR1 and the kinase-encoding BRSK1 are considered putative tumor suppressor genes (TSGs). However, EGR1 and BRSK1 mutations that could inactivate their functions are not reported in colorectal (CRC) and gastric (GC) cancers. Methods: There are mononucleotide repeats in EGR1 and BRSK1, which could be mutated in cancers with defects in mismatch repair, resulting in microsatellite instability (MSI). We analyzed 124 CRCs and 79 GCs for mutations and their intratumoral heterogeneities (ITHs). Results: Twenty-one out of 79 CRCs (26.6%) and 5 out of 34 GCs (14.7%) carrying high MSI (MSI-H) exhibited frameshift mutations. However, we found no such mutations in cancers with microsatellite stability. In addition, we studied ITH for these mutations in 16 cases of CRCs and observed that EGR1 and BRSK1 mutations exhibited ITH in 3 (18.8%) and 2 (12.5%) cases, respectively. Conclusion: Our data in this study reveal that the TSG genes EGR1 and BRSK1 carry mutational ITH as well as frameshift mutations in MSI-H CRC and GC, which together may be features of GC and CRC with MSI-H. These results suggest that frameshift mutations of EGR1 and BRSK1 might play a role in tumorigenesis through TSG inactivation in CRC and GC.
© 2016 S. Karger AG, Basel
- Sukhatme VP, Cao XM, Chang LC, Tsai-Morris CH, Stamenkovich D, Ferreira PC, Cohen DR, Edwards SA, Shows TB, Curran T, Le Beau MM, Adamson ED: A zinc finger-encoding gene coregulated with c-fos during growth and differentiation, and after cellular depolarization. Cell 1988;53:37-43.
- Liu C, Yao J, de Belle I, Huang RP, Adamson E, Mercola D: The transcription factor EGR-1 suppresses transformation of human fibrosarcoma HT1080 cells by coordinated induction of transforming growth factor-beta1, fibronectin, and plasminogen activator inhibitor-1. J Biol Chem 1999;274:4400-4411.
- Liu C, Yao J, Mercola D, Adamson E: The transcription factor EGR-1 directly transactivates the fibronectin gene and enhances attachment of human glioblastoma cell line U251. J Biol Chem 2000;275:20315-20323.
- Shareef MM, Cui N, Burikhanov R, Gupta S, Satishkumar S, Shajahan S, Mohiuddin M, Rangnekar VM, Ahmed MM: Role of tumor necrosis factor-alpha and TRAIL in high-dose radiation-induced bystander signaling in lung adenocarcinoma. Cancer Res 2007;67:11811-11820.
- Huang RP, Fan Y, de Belle I, Niemeyer C, Gottardis MM, Mercola D, Adamson ED: Decreased Egr-1 expression in human, mouse and rat mammary cells and tissues correlates with tumor formation. Int J Cancer 1997;72:102-109.
- Gitenay D, Baron VT: Is EGR1 a potential target for prostate cancer therapy? Future Oncol 2009;5:993-1003.
- Riggs PK, Rho O, DiGiovanni J: Alteration of Egr-1 mRNA during multistage carcinogenesis in mouse skin. Mol Carcinog 2000;27:247-251.
- Scharnhorst V, Menke AL, Attema J, Haneveld JK, Riteco N, van Steenbrugge GJ, van der Eb AJ, Jochemsen AG: EGR-1 enhances tumor growth and modulates the effect of the Wilms' tumor 1 gene products on tumorigenicity. Oncogene 2000;19:791-800.
Liu C, Rangnekar VM, Adamson E, Mercola D: Suppression of growth and transformation and induction of apoptosis by EGR-1. Cancer Gene Ther 1998;5:3-28.
- Virolle T, Krones-Herzig A, Baron V, De Gregorio G, Adamson ED, Mercola D: Egr1 promotes growth and survival of prostate cancer cells. Identification of novel Egr1 target genes. J Biol Chem 2003;278:11802-11810.
- Myung DS, Park YL, Kim N, Chung CY, Park HC, Kim JS, Cho SB, Lee WS, Lee JH, Joo YE: Expression of early growth response-1 in colorectal cancer and its relation to tumor cell proliferation and apoptosis. Oncol Rep 2014;31:788-794.
- Myung E, Park YL, Kim N, Chung CY, Park HB, Park HC, Myung DS, Kim JS, Cho SB, Lee WS, Joo YE: Expression of early growth response-1 in human gastric cancer and its relationship with tumor cell behaviors and prognosis. Pathol Res Pract 2013;209:692-699.
- Barnes AP, Lilley BN, Pan YA, Plummer LJ, Powell AW, Raines AN, Sanes JR, Polleux F: LKB1 and SAD kinases define a pathway required for the polarization of cortical neurons. Cell 2007;129:549-563.
- Lu R, Niida H, Nakanishi M: Human SAD1 kinase is involved in UV-induced DNA damage checkpoint function. J Biol Chem 2004;279:31164-31170.
- Müller M, Lutter D, Püschel AW: Persistence of the cell-cycle checkpoint kinase Wee1 in SadA- and SadB-deficient neurons disrupts neuronal polarity. J Cell Sci 2010;123:286-294.
- Alvarado-Kristensson M, Rodríguez MJ, Silió V, Valpuesta JM, Carrera AC: SADB phosphorylation of gamma-tubulin regulates centrosome duplication. Nat Cell Biol 2009;11:1081-1092.
- Imai K, Yamamoto H: Carcinogenesis and microsatellite instability: the interrelationship between genetics and epigenetics. Carcinogenesis 2008;29:673-680.
- Marusyk A, Almendro V, Polyak K: Intra-tumour heterogeneity: a looking glass for cancer? Nat Rev Cancer 2012;12:323-334.
- McGranahan N, Swanton C: Biological and therapeutic impact of intratumor heterogeneity in cancer evolution. Cancer Cell 2015;27:15-26.
- Kim TM, Jung SH, Baek IP, Lee SH, Choi YJ, Lee JY, Chung YJ, Lee SH: Regional biases in mutation screening due to intratumoural heterogeneity of prostate cancer. J Pathol 2014;233:425-435.
- Murphy K, Zhang S, Geiger T, Hafez MJ, Bacher J, Berg KD, Eshleman JR: Comparison of the microsatellite instability analysis system and the Bethesda panel for the determination of microsatellite instability in colorectal cancers. J Mol Diagn 2006;8:305-311.
- Yoo NJ, Kim HR, Kim YR, An CH, Lee SH: Somatic mutations of the KEAP1 gene in common solid cancers. Histopathology 2012;60:943-952.
- Kim MS, An CH, Chung YJ, Yoo NJ, Lee SH: NIPBL, a cohesion loading factor, is somatically mutated in gastric and colorectal cancers with high microsatellite instability. Dig Dis Sci 2013;58:3376-3378.
- Choi MR, Qwak M, Yoo NJ, Lee SH: Regional bias of intratumoral genetic heterogeneity of apoptosis-related genes BAX, APAF1, and FLASH in colon cancers with high microsatellite instability. Dig Dis Sci 2015;60:1674-1679.
- Choi MR, An CH, Yoo NJ, Lee SH: Laminin gene LAMB4 is somatically mutated and expressionally altered in gastric and colorectal cancers. APMIS 2015;123:65-71.
- Mahalingam D, Natoni A, Keane M, Samali A, Szegezdi E: Early growth response-1 is a regulator of DR5-induced apoptosis in colon cancer cells. Br J Cancer 2010;102:754-764.
- Calin GA, Gaf R, Tibiletti MG, Herlea V, Becheanu G, Cavazzini L, Barbanti-Brodano G, Nenci I, Negrini M, Lanza G: Genetic progression in microsatellite instability high (MSI-H) colon cancers correlates with clinico-pathological parameters: a study of the TGRbetaRII, BAX, hMSH3, hMSH6, IGFIIR and BLM genes. Int J Cancer 2000;89:230-235.
- Ahmed MM: Regulation of radiation-induced apoptosis by early growth response-1 gene in solid tumors. Curr Cancer Drug Targets 2004;4:43-52.
Article / Publication Details
Copyright / Drug Dosage / DisclaimerCopyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.